SMUP-IV-01

SMUP-IV-01 is an allogeneic umbilical cord blood-derived mesenchymal stem cell therapy developed for intravenous infusion. It is under development for the treatment and prevention of diabetic nephropathy, a complication of diabetes that affects kidney function. The drug utilizes the regenerative and immunomodulatory properties of mesenchymal stem cells to potentially ameliorate or prevent kidney damage associated with diabetic nephropathy. As of early 2025, SMUP-IV-01 is in early Phase 1 clinical trials, with non-clinical results ongoing[1][2]. The developer and active organization behind this therapy is MEDIPOST. The mechanism of action has not been explicitly detailed in public sources as of April 2025; however, based on its modality (mesenchymal stem cell therapy), it likely acts through paracrine signaling, immunomodulation, and tissue repair processes typical for MSC-based therapies[1][2].